Recent Insights into Kidney Injury and Repair from Transcriptomic Analyses

Yuhei Kirita^a Monica Chang-Panesso^a Benjamin D. Humphreys^{a, b}

^aDivision of Nephrology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; ^bDepartment of Developmental Biology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA

Keywords

Acute Kidney Injury · Transcriptomics · RNA-sequencing

Abstract

Injured tubular epithelium exhibits cellular plasticity in that it can dedifferentiate, reenter the cell cycle, and subsequently either redifferentiate or adopt a chronically injured phenotype. Although some nephrogenic genes are reexpressed during injury and repair, developmental pathways are only partially recapitulated and the process is more accurately viewed as an entirely new program intrinsic to the regenerative response to injury. Recent advances in our understanding of the molecular circuitry underpinning epithelial plasticity have come from bulk, cell-specific, and single-cell transcriptomic analyses. These results have begun to define the signaling pathways and gene regulatory networks governing the epithelial injury response. In this review, we highlight recent transcriptomic analyses in kidney injury, repair and fibrosis, and outline the ways that these studies are improving our understanding of kidney regeneration.

© 2019 S. Karger AG, Basel

Introduction

Acute kidney injury (AKI) is highly prevalent and occurs in 1 in 5 adults and 1 in 3 children hospitalized with acute illness [1]. An episode of AKI can predict not only the future development of chronic kidney disease (CKD) but also mortality [2]. It is increasingly recognized that incomplete or maladaptive repair, characterized by ongoing localized tubule injury, might explain the epidemiologic link between AKI and future risk of CKD [3–5]. Technological advances in transcriptomics, such as RNA-sequencing (RNA-seq), ribosome profiling, and single cell RNA-sequencing (scRNA-seq), are now providing much more comprehensive information about the molecular events occurring during AKI and repair than previously possible [6]. These advances should ultimately enable development of therapeutic strategies to harness

Contribution from the AKI and CRRT 2019 Symposium at the 24th International Conference on Advances in Critical Care Nephrology, Manchester Grand Hyatt, San Diego, CA, USA, February 26 – March 1, 2019. This symposium was supported in part by the NIDDK funded University of Alabama at Birmingham–University of California San Diego O'Brien Center for Acute Kidney Injury Research (P30DK079337).

repair mechanisms to promote successful recovery from AKI while suppressing maladaptive responses that can lead to failed repair and fibrosis [7, 8].

Bulk RNA-Seq Studies in AKI

Two recent studies from the McMahon Laboratory have used bulk RNA-seq to characterize the full course of human AKI in great detail. This approach entails extraction of all mRNA from a kidney sample followed by cDNA library generation and sequencing. Its advantages include simplicity, ability to perform on cryopreserved samples, and the ability to sequence very deeply and detect nearly all transcripts present. The primary disadvantage is that this approach is unable to identify the response of an individual kidney cell type because gene expression signatures are integrated from all the cells present in the sample. In these 2 studies, they analyzed the transcriptomes from 42 kidney transplant recipients at 4 separate time points: before and after implantation and 3 and 12 months after transplantation.

In 1 study, Cippà et al. [9] applied an elegant computational approach based on single cell RNA-seq analysis to identify and characterize shared trajectories of disease progression among these 42 disparate datasets. The primary finding was that distinct gene signatures differentiate successful repair after reperfusion (the transplant itself was appropriately categorized as an AKI) from failed repair characterized by progression to CKD. In particular, genes related to mitochondrial homeostasis, senescence, and inflammation predominated in biopsies from patients that progressed to CKD.

A second study analyzed this same dataset in more detail, focusing on B cell-associated transcripts that segregated with patients that developed CKD compared with those that underwent successful repair [10]. They sought to answer whether a B cell alloimmune response was an intrinsic component of CKD progression, or alternatively that the host immune response actively causes allograft damage, sustaining CKD transition. They garnered several independent lines of evidence supporting the latter interpretation, that is, that the late B cell immune response is pathogenic, related to ongoing tissue injury and driving fibrosis. These lines of evidence included (a) a lack of histologic evidence of B cell-mediated immunity, (b) the presence of ectopic lymphoid tissue composed predominantly of B cells in late stages after AKI, (c) evidence for clonal expansion of B cell subsets, based on B cell receptor repertoire sequencing, and (d) the presence of autoantibodies in a long-term mouse

model or AKI – despite the fact that this was an autologous, nontransplant model. This important result shows the power of transcriptomic analyses to reveal novel (and in this case somewhat unexpected) biologic insight.

Proximal Tubule-Specific RNA-Seq in AKI

Recently, we have applied the translating ribosome affinity purification method to transcriptionally profile injured proximal tubule (PT) during AKI. This method involves the affinity purification of mRNA bound to ribosomes by expression of a tagged ribosomal fusion protein expressed specifically in PT but not other kidney cell types. We have previously validated this approach in both podocytes and myofibroblasts [11, 12]. Using a Kim-1-CreER^{t2} knockin mouse line that we generated, we could specifically profile injured PT over the course of acute injury and repair, since Kim-1 (gene name *Havcr-1*) is only expressed in injured PT [13].

We validated our approach by showing that acutely injured and genetically labeled PT coexpressed Kim-1, Vimentin, Sox9, and Ki67, indicating a dedifferentiated and proliferative state. Translational profiling during injury and repair revealed signatures of both successful and unsuccessful maladaptive repair. It is also possible that some of these transcriptomic changes represent neither successful nor maladaptive repair, but rather adaptive responses of the cell to the injury environment. We were particularly interested in the gene regulatory network governing repair, and so we specifically analyzed upregulated transcription factors. This identified forkhead box protein M1 (FoxM1) as one of the most highly upregulated transcription factors in injured PT. FoxM1 in some cellular contexts regulates cell cycle progression. We could also identify known downstream targets of FoxM1: *Ccnb1*, *Plk1*, *Aurkb*, which are also all cell cycle-related proteins. To test whether FoxM1 regulates epithelial proliferation, we performed siRNA knockdown of Foxm1 in human proximal tubular epithelial cells, which indeed suppressed proliferation *in vitro*. These results implicate FoxM1 as a novel PT-specific regulator of injury-induced cell proliferation.

scRNA-Seq

Finally, recent technological advances now allow massively parallel scRNA-seq, and this is beginning to be applied to better understand mammalian kidney injury and repair. An important limitation has been the generation of a single cell suspension that contains all kidney cell types

Fig. 1. Cell-type expression pattern of FoxM1 by single nucleus RNA-seq of day 14 unilateral ureteral obstruction mouse kidney. The only kidney cell type that expresses appreciable FoxM1 is the “proliferating PT” cell cluster, suggesting a role for FoxM1 in regulating PT proliferation after injury. Data are from the Kidney Interactive Transcriptomics website (<http://humphreyslab.com/SingleCell/>). Pct. exp., percent expression; avg. exp. scale, average expression scale; Pod, podocyte; EC, endothelial cell; PT, proximal tubule; DL, descending loop; tAL, thin ascending loop; TAL, thick ascending loop; DCT, distal convoluted tubule; CNT, connecting segment; CD-PC, collecting duct-principal cell; IC, intercalated cell; Act. Fib., activated fibroblasts; JGA, juxtaglomerular apparatus; Mφ, macrophage; FoxM1, forkhead box protein M1.

and that preserves RNA integrity. Unfortunately, generating single cell suspensions has turned out to be very difficult in adult kidney, and even more challenging in post-ischemic kidney which contains inflammatory cells and can be fibrotic. We have recently shown that generating nuclear preparations circumvents these limitations, because the dissociation uses NP40 detergent and dounce homogenization – which frees even cells embedded in fibrotic matrix – while preventing RNA degradation [14].

We used nuclear preparations to perform scRNA-seq on mouse kidney subjected to unilateral ureteral obstruction. We could identify many PT epithelia in this dataset, including 2 novel PT subclusters. We annotated one of these subclusters as “proliferating PT” because it expressed a proliferation cell signature. Reassuringly, this

cluster exclusively expresses FoxM1, validating our prior identification of this transcription factor by translating ribosome affinity purification of injured PT (Fig. 1).

Future Questions

We expect that the first transcriptional atlases of kidney injury and repair at the single cell level will become available in the near term. These are sure to lead to greater insight concerning the molecular pathways that underlie successful and failed epithelial repair. But transcriptomic data may not answer the more fundamental question of whether epithelial cell plasticity during repair reflects different transient cell states, or whether injury can induce a fundamentally different epithelial cell type. For example, for the failed PT gene signature that we have recently identified, does this represent a transient injury state that persists because of ongoing injury, or is it an entirely new, stable cell type that promotes fibrosis?

One way to conceptualize the difference between a transient cell state and a distinct cell type is the spectrum of genes that are available to be expressed by that cell at any moment. Chromatin accessibility is one determinant of whether a gene can be expressed. For example, inactive genes maintained in an open chromatin configuration are immediately available to be expressed by that cell, but genes sequestered in closed chromatin are not. So one way to ask whether a PT cell that has failed to repair is a fundamentally new cell type is whether its epigenetic profile – its global chromatin accessibility profile – is different from either an acutely injured or a healthy PT cell. A variety of new technologies are now available to scan the epigenome – including at the single cell level. We predict that these techniques represent a potentially powerful new approach to understand the fundamental cell biology of kidney injury and repair. Since drugs targeting the epigenome [15] are in development, these kinds of studies hold promise for novel therapeutic approaches in AKI.

Acknowledgments

Work in the Humphreys Lab is supported by NIH/NIDDK grants DK103740 and DK107374 and by the NIDDK Diabetic Complications Consortium (DiaComp, www.diacomp.org) grants DK076169 and DK115255 (all to B.D.H.).

Disclosure Statement

The authors have no conflicts of interest to declare.

References

- 1 Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al.; Acute Kidney Injury Advisory Group of the American Society of Nephrology. World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol*. 2013 Sep;8(9):1482–93.
- 2 Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis*. 2009 Jun;53(6):961–73.
- 3 Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. *Kidney Int*. 2009 Nov;76(10):1089–97.
- 4 Hsu RK, Hsu CY. The Role of Acute Kidney Injury in Chronic Kidney Disease. *Semin Nephrol*. 2016 Jul;36(4):283–92.
- 5 Basile DP, Bonventre JV, Mehta R, Nangaku M, Unwin R, Rosner MH, et al.; ADQI XIII Work Group. Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. *J Am Soc Nephrol*. 2016 Mar;27(3):687–97.
- 6 Wu H, Humphreys BD. The promise of single-cell RNA sequencing for kidney disease investigation. *Kidney Int*. 2017 Dec;92(6):1334–42.
- 7 Chang-Panesso M, Humphreys BD. Cellular plasticity in kidney injury and repair. *Nat Rev Nephrol*. 2017 Jan;13(1):39–46.
- 8 Humphreys BD. Mechanisms of Renal Fibrosis. *Annu Rev Physiol*. 2018 Feb;80(1):309–26.
- 9 Cippà PE, Sun B, Liu J, Chen L, Naesens M, McMahon AP. Transcriptional trajectories of human kidney injury progression. *JCI Insight*. 2018 Nov;3(22):123151.
- 10 Cippà PE, Liu J, Sun B, Kumar S, Naesens M, McMahon AP. A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation. *Nat Commun*. 2019 Mar;10(1):1157.
- 11 Grgic I, Genovese G, Pollak MR, Humphreys BD, editors. *Translational Profiling of Podocytes in Focal Segmental Glomerulosclerosis*. Philadelphia, Pennsylvania: American Society of Nephrology; 2011.
- 12 Grgic I, Krautzberger AM, Hofmeister A, Lalli M, DiRocco DP, Fleig SV, et al. Translational profiles of medullary myofibroblasts during kidney fibrosis. *J Am Soc Nephrol*. 2014 Sep;25(9):1979–90.
- 13 Chang-Panesso M, Kadyrov FF, Lalli M, Wu H, Ikeda S, Kobayashi A, et al. FoxM1 drives proximal tubule proliferation during repair from acute kidney injury. *bioRxiv*. 2018: 436576.
- 14 Wu H, Kirita Y, Donnelly EL, Humphreys BD. Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis. *J Am Soc Nephrol*. 2019 Jan;30(1):23–32.
- 15 Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S. Use of epigenetic drugs in disease: an overview. *Genet Epigenet*. 2014 May;6:9–19.